Literature DB >> 11424113

Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses.

L Kaiser1, R S Fritz, S E Straus, L Gubareva, F G Hayden.   

Abstract

In experimental human influenza infection initiated by nasal inoculation, the magnitude of viral replication, fever, and symptoms correlate with nasopharyngeal lavage fluid levels of various cytokines. Our aim was to assess these relationships in patients with naturally occurring acute influenza. Patients with culture-positive influenza illness of less than 36 hr of duration were studied. Nasopharyngeal washing were collected at enrollment and on Day 2, 4, 6 and 8 for quantitative virus isolation and IL-6, TNF-alpha, INF-alpha, INF-gamma and IL-10 determinations. Blood samples collected at entry and on Day 2 and 6 were processed to assess plasma cytokines and circulating influenza RNA. Patients received either oseltamivir or placebo for 5 days. We assessed the correlation between nasopharyngeal lavage fluid or blood levels of cytokines before treatment and viral titers, symptom severity and fever. Sixteen adult subjects (median age of 22 years) were studied. In this small group of patients no significant differences between placebo and oseltamivir patients were found in viral replication or measures of cytokines. Thus the data for all 16 subjects were pooled for analysis. At entry, influenza A viruses were cultured from nasopharyngeal washes at a median titer of 4.8 log(10)TCID(50)/ml of wash. Viral titers correlated positively with symptom score (P = 0.006) and temperature values (P < 0.001). Viral titers, fever and symptoms were highest at enrollment and fell in parallel during the subsequent days. RT-PCR assays failed to detect influenza RNA in the white blood cells from any patient. We observed a significant release, in both nasopharyngeal lavage fluid and in plasma, of IL-6, TNF-alpha, INF-alpha, INF-gamma and IL-10. At entry high IL-6 levels were detected in the nasopharyngeal lavage fluid (median 10.3 pg/ml) and plasma (median 5.1 pg/ml) of all patients. We found a positive correlation between plasma IL-6 levels and both symptom scores and temperature values (P < 0.05), as well as a positive correlation between nasopharyngeal lavage fluid levels of IL-6 and TNF-alpha and temperature (P < 0.05). We did not find significant associations between symptoms, fever and levels of INF-alpha, INF-gamma or IL-10. The magnitude of early decrease in viral titers correlated with initial levels of INF-gamma in nasopharyngeal lavage fluid (P < 0.05). Significant production of IL-6, TNF-alpha, INF-alpha, INF-gamma and IL-10 occurs in response to community acquired influenza A illness. As in experimental influenza, symptoms and fever in natural acute influenza correlate with the release of IL-6. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11424113     DOI: 10.1002/jmv.1045

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  133 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Statins and influenza: can we move forward?

Authors:  Edward E Walsh
Journal:  J Infect Dis       Date:  2011-12-13       Impact factor: 5.226

Review 3.  The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines.

Authors:  Janet E McElhaney; Xin Zhou; H Keipp Talbot; Ernst Soethout; R Chris Bleackley; David J Granville; Graham Pawelec
Journal:  Vaccine       Date:  2012-01-27       Impact factor: 3.641

4.  Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus.

Authors:  Masaki Mibayashi; Luis Martínez-Sobrido; Yueh-Ming Loo; Washington B Cárdenas; Michael Gale; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Infection-induced proinflammatory cytokines are associated with decreases in positive affect, but not increases in negative affect.

Authors:  Denise Janicki-Deverts; Sheldon Cohen; William J Doyle; Ronald B Turner; John J Treanor
Journal:  Brain Behav Immun       Date:  2006-10-18       Impact factor: 7.217

6.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.

Authors:  Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

7.  Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.

Authors:  Kevin B Walsh; John R Teijaro; Peter R Wilker; Anna Jatzek; Daniel M Fremgen; Subash C Das; Tokiko Watanabe; Masato Hatta; Kyoko Shinya; Marulasiddappa Suresh; Yoshihiro Kawaoka; Hugh Rosen; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

Review 8.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.

Authors:  Shankar Subramanian Iyer; Gehong Cheng
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 9.  Immunogenetics of seasonal influenza vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

10.  The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations.

Authors:  Tuula K Outinen; Satu M Mäkelä; Ilpo O Ala-Houhala; Heini Sa Huhtala; Mikko Hurme; Antti S Paakkala; Ilkka H Pörsti; Jaana T Syrjänen; Jukka T Mustonen
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.